Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics, a French biotech, have announced enrollment of the first patient... View Article
New member | BioMAdvanced Diagnostics
BioMAdvanced Diagnostics aims to become a major player in biomarkers diagnostics, in France and internationally, starting with tests of immune... View Article
Valneva commences rolling submission to MHRA for its inactivated, adjuvanted COVID-19 vaccine
Valneva, a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling submission, for initial approval of... View Article
Valneva and Pfizer complete recruitment for Phase 2 Trial of Lyme disease vaccine candidate
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study
OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article
Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.
Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article
Valneva continues ongoing discussions with the European Commission for inactivated COVID-19 vaccine candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
French biotech XENOTHERA accelerates its development with fundraising of 20 million euros
XENOTHERA is developing a technological platform of exclusive “glyco-humanized” antibodies built on dual expertise in genetics and immunology. The financing... View Article